Additional Details
-
Better Breathers Club - Clevand Clinic Ohio | In-Person
View DetailsCleveland Clinic Richard E Jacobs | 33100 Cleveland Clinic BlvdCleveland OH. 44011 -
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
Trial Management Group IncWindsor ON. N8X1T3View Details -
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
Mannkind CorporationDanbury CT. 06810View Details -
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Pulmonary Specialists of The Palm BeachesLoxahatchee Groves FL. 33470View Details -
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Clinical Research of Gastonia (CRG)Gastonia NC. 28054View Details -
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Elevate Clinical ResearchHouston TX. 77058View Details -
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
El Paso Pulmonary Association, PAEl Paso TX. 79902View Details -
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Clinical Research and Associates, Inc.Miami FL. 33126View Details -
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
Massachusetts General HospitalBoston MA. 02114View Details -
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia
State University of New York at Buffalo Jacobs School of Medicine and Biomedical SciencesBuffalo NY. 14203View Details -
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
National Institutes of Health Clinical CenterBethesda MD. 20892View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteKingston ON. K7M 4E7View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteDenver CO. 80206View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteDallas TX. 75254View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteVancouver BC. V5Z 1M9View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteBethlehem PA. 18015View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteOklahoma City OK. 73117View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteBoston MA. 02114View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SitePhiladelphia PA. 19104View Details -
The ARGiNAUT study is testing AZD8965 in adults with idiopathic pulmonary fibrosis who may or may not be taking treatments to reduce the buildup of scar tissue in the lungs.
Research SiteBurlington VT. 05401View Details